TY  - GEN
AU  - Hernández, Domingo
AU  - Ruiz-Esteban, Pedro
AU  - Gaitán, Daniel
AU  - Burgos, Dolores
AU  - Mazuecos, Auxiliadora
AU  - Collantes, Rocío
AU  - Briceño, Eva
AU  - Palma, Eulalia
AU  - Cabello, Mercedes
AU  - González-Molina, Miguel
AU  - De Mora, Manuel
PY  - 2014
DO  - 10.1186/1471-2369-15-65
UR  - http://hdl.handle.net/20.500.12105/17066
AB  - BACKGROUND: Left ventricular hypertrophy (LVH) is common in kidney transplant (KT) recipients. LVH is associated with a worse outcome, though m-TOR therapy may help to revert this complication. We therefore conducted a longitudinal study to assess...
LA  - eng
PB  - BioMed Central (BMC)
KW  - Everolimus
KW  - Left ventricular hupertrophy
KW  - Renin-angiotensis blockers
KW  - Sirolimus
KW  - Kidney transplantation
KW  - Inhibidores de la enzima convertidora de angiotensina
KW  - Farmacoterapia combinada
KW  - Hipertrofia ventricular izquierda
KW  - Inmunosupresores
KW  - Trasplante de riñón
KW  - Inhibidores de proteínas cinasas
KW  - TOR serina-treonina cinasas
KW  - Resultado del tratamiento
KW  - Antagonistas de receptores de angiotensina
KW  - Angiotensin-Converting Enzyme Inhibitors
KW  - Drug Therapy, Combination
KW  - Female
KW  - Humans
KW  - Hypertrophy, Left Ventricular
KW  - Immunosuppressive Agents
KW  - Kidney Transplantation
KW  - Longitudinal Studies
KW  - Middle Aged
KW  - Protein Kinase Inhibitors
KW  - TOR Serine-Threonine Kinases
KW  - Treatment Outcome
KW  - Angiotensin Receptor Antagonists
TI  - Regression of cardiac growth in kidney transplant recipients using anti-m-TOR drugs plus RAS blockers: a controlled longitudinal study.
TY  - research article
ER  -